Today’s stock market news brings together major developments across capital markets, financial regulation, currencies, banking and corporate India. NSE ended its first trading session with modest gains, while PB Fintech witnessed a sharp sell-off following proposed changes to insurance distributor commissions. SEBI has also expanded the investment framework for portfolio managers, while the rupee came under pressure amid elevated crude oil prices and US bond yields. Jarvis Invest looks at the key developments shaping Indian markets and the broader economy today.
Stock Market News: NSE Ends Debut at ₹1,818 After Muted Listing on BSE
The stock of NSE had a quiet listing on Thursday. The stock listed on BSE and was permitted to trade (PTT) on the MSEI. The stock had a modest opening at ₹1,800, against the issue price of ₹1,785. During the day, the stock touched a high of ₹1,878, notching up gains of 5.21% at its highest point. However, selling pressure led to the stock closing at ₹1,818, with opening day gains of just 1.85%. A total of 5.15 crore shares changed hands on the BSE, entailing a turnover of ₹9,483 crore for the day. NSE had an opening day market cap of ₹4,49,955 crore as of close.
Stock Market News: PB Fintech Crashes 36% as IRDAI Proposes Insurance Commission Caps
With IRDA proposing sweeping changes in distributor commission structure, PB Fintech (owner of Policybazaar) was the worst hit. The stock cracked by 36% to touch an 18-month low of ₹1,207 per share. IRDA proposed that health insurance payouts be capped at 15-20% and term life commissions be capped at 25%. That would be a substantial reduction for distributors, and Policybazaar would be the worst hit. These rate caps are to protect consumers, but big distributors are taking it on their chin. It saw market cap erosion of about ₹32,000 crore in one day.
Stock Market News: SEBI Overhauls PMS Rules, Opens Access to IPOs, Foreign Securities and Unlisted Debt
The SEBI board meet approved new PMS rules, broadening the playground. Portfolio managers will be permitted to invest client money in IPOs, foreign securities, and primary debt issuances. They will also be allowed to invest in direct plans of mutual funds. PMS plans can also invest up to 10% of client assets in unlisted debt, subject to client consent. Exposure to exchange traded derivatives (ETD) is allowed up to 1.25X the client’s AUM. SEBI has also permitted independent fund managers (IFMs), who can operate a client portfolio in association with a registered PMS.
Stock Market News: Tata Sons PusheStock Market News: Rupee Slides to Record Low as Crude Oil and US Bond Yields Add Pressures Back Against Noel Tata’s Objections Over Chairman Reappointment
It now looks like a full-blown rebellion by the directors of Tata Sons against the ownership group represented by Noel Tata. After Noel Tata wrote to Tata Sons objecting to the manner in which Chandra was given another 5-year term; Tata Sons has refuted these charges. According to Tata Sons, the special process outlined in the Articles of Association were only valid for a new appointee and Chandra was just a case of reappointment. Since it was just a routine reappointment, the AOA would not hold and the casting vote by Manwani was good enough as a decision.
Stock Market News: Rupee Slides to Record Low as Crude Oil and US Bond Yields Add Pressure
It was a tough day for the Indian rupee as it closed at an all-time low of ₹96.11/$. This is despite the apparent comfort of $136 billion having come into India through the FCNR(B) route. Two factors triggered the sharp weakening of the rupee. Firstly, the price of Brent Crude surged to $104/bbl after the situation in the Middle East showed no signs of respite. Secondly, the rupee was also hit by the US bond yields touching a 19-year high of 5.15%. In addition, the new IRDA rules on insurance commissions resulted in a massive sell-off in the Nifty on Thursday.
India’s Semiconductor Ambitions Face Supply-Chain Challenge as Chip Demand Heads Toward $120 Billion
The biggest risk to India’s semiconductor ambitions, according to a report by JM Financial, may come from absence of robust local supply chain. It is estimated that Indian semiconductor demand will nearly triple to $120 billion by 2030, making India one of the major markets for chips. However, for that to happen, the supply chain ecosystem is still too dependent on China, which may not be sustainable at that scale. Hence, a domestic supply chain may be the answer. The Tata Electronics chip facility at Dholera will need the support of over 400 vendors, which is a missing link.
Indian Pharma Revenue Set to Grow 11–13% in FY27 Even as Margins Face Cost Pressure
According to a report by CRISIL, revenues of the Indian pharma sector is likely to grow 11-13% in FY27. This is likely to be assisted by strong domestic demand and exports. However, the spike in raw material costs is likely to squeeze the operating margins by about 200 bps to 21.5% in FY27. Cash flows will continue to be strong for pharma companies and debt to EBITDA ratio for pharma stocks will remain steady around 1.2X. While domestic growth is expected at around 10-11%, exports growth will be much quicker at 14-16% in FY27, with an 83% share of formulations.
Banks Prepare to Deploy FCNR(B) Liquidity as Festive Credit Demand Picks Up
RBI deputy governor, Rohit Jain, has affirmed that banks will start deploying their FCNR(B) funds aggressively during the festive season. The swap of $130 billion had resulted in surplus liquidity of nearly ₹11 trillion with the banks after adjusting for the funds that were soaked by the VRRR operations of the RBI. Jain also affirmed that credit demand had been robust across consumer and corporate loans. The deployment of additional liquidity would be largely determined by the asset liability positions of the bank. Banks are, however, cautious on credit deployment.
Conclusion
Today’s developments highlight the interaction between regulation, global macro conditions and domestic growth opportunities. NSE’s market debut and SEBI’s revised PMS framework mark important developments for India’s capital markets, while the pressure on PB Fintech demonstrates how regulatory changes can quickly affect business models and valuations. Meanwhile, India’s semiconductor supply-chain challenge, the pharma sector’s growth outlook and the deployment of FCNR(B) liquidity by banks remain important themes to track. Stay updated with Jarvis Invest for the latest stock market news and insights into developments shaping Indian markets.
